Osteoporosis in health and disease: a dermatologist's perspective

Dermatol Clin. 2006 Apr;24(2):241-9, vii. doi: 10.1016/j.det.2006.01.013.

Abstract

Osteoporosis affects more than 75 million people in the United States, Asia, and Europe. Osteoporosis results from a combination of genetic and environmental factors that contribute to peak bone mass and the rate of bone loss. These factors include medications, diet, race, sex, lifestyle, and physical activity. The management of osteoporosis can be complicated by simultaneous treatment of other diseases. For dermatologists, the use of long-term oral corticosteroids for the management of immunobullous and blistering diseases is of particular importance. Although these treatment modalities are potentially lifesaving for patients, the side effects can be dangerous. This article examines the pathophysiology, clinical course, and treatments for osteoporosis and the special considerations that arise when managing patients using corticosteroids.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Adrenal Cortex Hormones / adverse effects*
  • Dermatology
  • Humans
  • Osteoporosis / chemically induced
  • Osteoporosis / diagnosis*
  • Osteoporosis / pathology
  • Osteoporosis / prevention & control*
  • Skin Diseases / drug therapy*

Substances

  • Adrenal Cortex Hormones